<DOC>
	<DOCNO>NCT01355588</DOCNO>
	<brief_summary>This phase 1 , double-blind , 4-way crossover study healthy male female volunteer . Subjects receive 4 formulation intranasal ketorolac tromethamine 30 mg . There wash-out period 3-7 day dose . On Day 1 period subject randomise receive either single intranasal dose 30 mg ketorolac tromethamine alone single intranasal dose 30 mg ketorolac tromethamine 4 % , 5 % 6 % lidocaine hydrochloride . At end study subject receive 4 treatment . The primary objective study healthy volunteer compare safety , tolerability , pharmacokinetics 4 formulation ketorolac tromethamine . A secondary objective monitor lidocaine hydrochloride plasma level .</brief_summary>
	<brief_title>Tolerability , Safety Pharmacokinetics Four Formulations Ketorolac Tromethamine Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<criteria>Male female volunteer , age 18 60 year inclusive Female subject child bear potential must negative urine pregnancy test prior entry study must breast feed All female subject child bear potential male subject female partner child bear potential must consent use medically acceptable method contraception ( oral implant contraceptive hormone , condom diaphragm spermicidal agent , intrauterine device surgical sterilisation ) throughout study period Subject give sign informed consent Subject within 20 % normal weight his/her height body build accord table `` Desirable Weights Men Women '' ( Metropolitan Life Insurance Co. 1999 ) Subject 's medical history consider normal , clinically significant abnormality Subject consider good health opinion Investigator determine prestudy physical examination clinically significant abnormality , vital sign within normal range ECG clinically significant abnormality Subject 's prestudy clinical laboratory finding within normal range , outside normal range , deem clinically significant opinion Investigator Subject bilateral patent nasal airways screen assess Investigator Body weight least 70 kg Subject clinically significant illness 4 week screen Use prescribe medication 3 week prior dose overthecounter preparation 7 day prior dose , except paracetamol allow 48 hour prior dose . However , use multivitamins oral contraceptive permit Subject significant history drug/solvent abuse , positive drug abuse test screening Subject history alcohol abuse drank excess 28 unit per week ( male ) 21 unit per week ( female ) Current tobacco use history smoking within past 5 year Subject , opinion Investigator , suitable participate study Subjects participate clinical study investigational drug/device within 3 month prior first day dose Subjects positive result HIV screen , Hepatitis B screen Hepatitis C screen Subjects serious adverse reaction significant hypersensitivity drug Subjects donate 500 mL blood within 3 month prior screen Any history coexist nasal polyp , NSAID sensitivity asthma Allergic reaction aspirin NSAIDs Current upper respiratory tract infection respiratory tract condition could interfere absorption nasal spray assessment AEs Any suspicion rhinitis medicamentosa ( chronic daily use topical decongestant ) Use monoamine oxidase inhibitor 14 day prior study entry Active peptic ulcer disease , gastrointestinal bleeding perforation , history peptic ulcer disease gastrointestinal bleeding Anemia due unexplained known gastrointestinal bleeding History asthma chronic pulmonary disorder Renal impairment risk renal failure due volume depletion Known sensitivity lidocaine hydrochloride</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>